Myriad Genetics, Inc. (MYGN) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Myriad Genetics, Inc. for the fiscal year ended December 31, 2024. Myriad is a leading molecular diagnostic testing and precision medicine company focused on three core areas: Oncology, Women's Health, and Pharmacogenomics. The company develops tests to assess disease risk, guide treatment decisions, and provide prenatal insights. As of December 31, 2024, the company employed approximately 2,700 full-time equivalents.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $837.6 million | $753.2 million | +11% |
| Net Loss | $(127.3) million | $(263.3) million | Improvement |
| Loss Per Share (Basic/Diluted) | $(1.41) | $(3.18) | - |
| Gross Margin | 69.9% | 68.6% | +1.3 pts |
| Operating Loss | $(123.5) million | $(257.4) million | Improvement |
| Cash and Cash Equivalents | $102.4 million | $132.1 million | -$29.7 million |
| Outstanding Debt (ABL Facility) | $40.5 million | $38.5 million | +$2.0 million |
| Available Credit (ABL Facility) | $56.0 million | Not Disclosed | - |
Revenue by Segment: Hereditary Cancer ($364.5M, +11%), Prenatal ($177.1M, +17%), Pharmacogenomics ($170.2M, +23%), and Tumor Profiling ($125.8M, -7%).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11% year-over-year, driven by volume growth and higher average revenue per test in Hereditary Cancer, Prenatal, and Pharmacogenomics segments. Tumor Profiling revenue declined 7% due to lower study volumes for the MyChoice CDx test.
- Impairment Charges: The company recognized $56.8 million in goodwill and long-lived asset impairment charges in 2024, compared to none in 2023. This included a $43.0 million impairment of the GeneSight developed technology intangible asset and a $12.4 million loss on the sale of the EndoPredict business.
- Legal Settlements: Legal settlement expenses decreased significantly to a benefit of $(21.3) million in 2024 compared to $112.8 million in 2023. The 2023 figure included a $77.5 million securities class action settlement and a $34.0 million Ravgen settlement. The 2024 benefit resulted from the reversal of a $21.3 million contingent payment liability related to the Ravgen settlement, deemed no longer probable.
- Acquisitions and Divestitures: In February 2024, Myriad acquired the Precise Tumor and Precise Liquid tests from Intermountain Healthcare. In August 2024, the company sold its EndoPredict business to Eurobio Scientific.
Guidance, Outlook, Risks, and Unusual Items
- UnitedHealthcare Coverage Change: A critical risk factor is UnitedHealthcare's decision to no longer cover certain multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, effective January 1, 2025, for commercial plans and H1 2025 for Medicaid plans. Myriad recognized approximately $45.0 million in GeneSight revenue from UnitedHealthcare in 2024. Management anticipates this will negatively impact revenue, profitability, and cash flow in 2025.
- Leadership Transition: On February 24, 2025, CEO Paul J. Diaz announced his resignation, effective April 30, 2025. Samraat S. Raha (current COO) will succeed him as CEO, and Mark S. Verratti (current CCO) will become COO.
- Regulatory Environment: The FDA issued a final rule in May 2024 to regulate Laboratory Developed Tests (LDTs) as medical devices, effective July 5, 2024. This requires a phased compliance over four years, potentially increasing costs and delaying new test launches. Litigation challenging this rule is ongoing.
- Liquidity: The company maintains a $115.0 million asset-based revolving credit facility (ABL) with $40.5 million outstanding as of year-end. Management believes existing cash and borrowing capacity are sufficient for the next 12 months, though future funding may be required if capital resources are consumed faster than expected.
Key Facts for Investor Verification
- UnitedHealthcare Impact: Verify the actual revenue impact of the UnitedHealthcare coverage change in Q1 and Q2 2025 earnings reports, as this directly affects the Pharmacogenomics segment's future viability.
- Impairment Reversal: Confirm the accounting treatment and future probability of the $21.3 million Ravgen contingent payment reversal, as a change in litigation status could reverse this benefit.
- Debt Covenants: Monitor compliance with the ABL Facility's fixed charge coverage ratio covenant, which is triggered if availability falls below specific thresholds.
- Leadership Execution: Assess the new leadership team's ability to execute the strategic growth plan and manage the transition of laboratory operations to new facilities planned for early 2025.
- Regulatory Compliance Costs: Track the financial impact of complying with the new FDA LDT regulations, including potential premarket approval costs and operational changes.